Literature DB >> 2471249

Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus.

A J Swaak1, A van Rooyen, L A Aarden.   

Abstract

One of the mediators responsible for the induction of the production of acute phase proteins by hepatocytes is interleukin-6 (IL-6), formally known as hybridoma growth factor (HGF). In a prospective study the biological significance of IL-6, but also the relationship with the acute phase response (C-reactive protein [CRP], alpha 1-antitrypsin and alpha 1-acid glycoprotein) during flare-ups in 12 systemic lupus erythematosus (SLE) patients was investigated. Only 2 SLE patients showed sustained elevated IL-6 levels, and in one of these patients a clear correlation was found between the increases in IL-6 and the acute phase response. In the other SLE patients hardly any response or change in the levels of IL-6, CRP, and/or alpha 1-antitrypsin was found. In contrast to the profiles of alpha 1-acid glycoprotein, in seven of the SLE patients a significant increase in the serum levels took place in the period preceding the exacerbation. This difference between the three acute phase proteins suggests that the regulatory mechanisms are different. Our results are in agreement with the findings that IL-6 might be responsible for the CRP response.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2471249     DOI: 10.1007/bf00270982

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  26 in total

1.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

2.  Hepatocyte-stimulating factor, beta 2 interferon, and interleukin-1 enhance expression of the rat alpha 1-acid glycoprotein gene via a distal upstream regulatory region.

Authors:  K R Prowse; H Baumann
Journal:  Mol Cell Biol       Date:  1988-01       Impact factor: 4.272

3.  Serum levels of interleukin-6 and acute phase responses.

Authors:  M W Nijsten; E R de Groot; H J ten Duis; H J Klasen; C E Hack; L A Aarden
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

4.  Molecular cloning and expression of hybridoma growth factor in Escherichia coli.

Authors:  J P Brakenhoff; E R de Groot; R F Evers; H Pannekoek; L A Aarden
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

5.  Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus.

Authors:  G J Becker; M Waldburger; G R Hughes; M B Pepys
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

6.  Solid phase radioimmunoassays for human C-reactive protein.

Authors:  B Shine; F C de Beer; M B Pepys
Journal:  Clin Chim Acta       Date:  1981-11-25       Impact factor: 3.786

Review 7.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

8.  Interleukin 6 (IL-6) in serum and urine of renal transplant recipients.

Authors:  M H Van Oers; A A Van der Heyden; L A Aarden
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

9.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

10.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

View more
  15 in total

1.  Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins.

Authors:  J K Lacki; W Samborski; S H Mackiewicz
Journal:  Clin Rheumatol       Date:  1997-05       Impact factor: 2.980

Review 2.  IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation.

Authors:  B E Barton
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Anaemia of chronic disease in rheumatoid arthritis. Raised serum interleukin-6 (IL-6) levels and effects of IL-6 and anti-IL-6 on in vitro erythropoiesis.

Authors:  G Vreugdenhil; B Löwenberg; H G van Eijk; A J Swaak
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

4.  A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases.

Authors:  Michael Lyman; Vincent Lieuw; Robyn Richardson; Anjuli Timmer; Christine Stewart; Steve Granger; Richard Woods; Michela Silacci; Dragan Grabulovski; Roland Newman
Journal:  J Biol Chem       Date:  2018-04-20       Impact factor: 5.157

Review 5.  The role of cytokines in the immunopathogenesis of lupus.

Authors:  B S Handwerger; V Rus; L da Silva; C S Via
Journal:  Springer Semin Immunopathol       Date:  1994

6.  The ratio of erythrocyte sedimentation rate to C-reactive protein is useful in distinguishing infection from flare in systemic lupus erythematosus patients presenting with fever.

Authors:  E Littlejohn; W Marder; E Lewis; S Francis; J Jackish; W J McCune; E C Somers
Journal:  Lupus       Date:  2018-03-16       Impact factor: 2.911

7.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

8.  Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.

Authors:  B K Finck; B Chan; D Wofsy
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

9.  Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus.

Authors:  K P Metsärinne; D C Nordström; Y T Konttinen; A M Teppo; F Y Fyhrquist
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?

Authors:  P E Spronk; E J ter Borg; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.